3/2
07:30 am
pvla
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Low
Report
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2/25
07:57 pm
pvla
Palvella Therapeutics Announces Pricing of Upsized Public Offering
High
Report
Palvella Therapeutics Announces Pricing of Upsized Public Offering
2/25
12:27 pm
pvla
Palvella Therapeutics (PVLA) had its price target raised by Mizuho from $205.00 to $250.00. They now have an "outperform" rating on the stock.
Medium
Report
Palvella Therapeutics (PVLA) had its price target raised by Mizuho from $205.00 to $250.00. They now have an "outperform" rating on the stock.
2/25
08:03 am
pvla
Palvella Therapeutics (PVLA) had its price target raised by BTIG Research from $192.00 to $215.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (PVLA) had its price target raised by BTIG Research from $192.00 to $215.00. They now have a "buy" rating on the stock.
2/24
05:02 pm
pvla
Palvella Therapeutics (PVLA) was given a new $210.00 price target by Truist Financial Corporation.
Medium
Report
Palvella Therapeutics (PVLA) was given a new $210.00 price target by Truist Financial Corporation.
2/24
04:05 pm
pvla
Palvella Therapeutics Announces Proposed Public Offering
Medium
Report
Palvella Therapeutics Announces Proposed Public Offering
2/24
02:40 pm
pvla
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $174.00 to $210.00. They now have a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $174.00 to $210.00. They now have a "buy" rating on the stock.
2/24
01:14 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $250.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $250.00 price target on by analysts at Stifel Nicolaus.
2/24
11:06 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/24
06:30 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
2/23
05:34 pm
pvla
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations [Yahoo! Finance]
High
Report
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations [Yahoo! Finance]
2/23
05:00 pm
pvla
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
High
Report
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
2/2
10:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at TD Cowen.
2/2
08:24 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Low
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
2/2
07:30 am
pvla
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Medium
Report
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
1/29
08:03 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/16
12:28 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/12
06:12 am
pvla
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
1/9
09:17 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
1/9
07:30 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
1/7
08:02 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
1/7
07:30 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Medium
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
12/23
10:44 am
pvla
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
Medium
Report
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
12/21
07:42 am
pvla
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
Medium
Report
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
12/20
09:41 pm
pvla
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]